SCHEMBL373410

SCHEMBL373410

CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.58
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
DUSP3 P51452 1/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
ALDH1A1 P00352 1/20 0.53
DGKA P23743 2/20 0.51
LPAR1 Q92633 2/20 0.49
LPAR6 P43657 1/20 0.49
LPAR4 Q99677 1/20 0.49
LPAR5 Q9H1C0 1/20 0.49
LPAR2 Q9HBW0 1/20 0.49
LPAR3 Q9UBY5 1/20 0.49
ENPP2 Q13822 1/20 0.49
PRKCA P17252 3/20 0.49
PRKCE Q02156 1/20 0.49
PRKCQ Q04759 1/20 0.49
PRKCD Q05655 1/20 0.49
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10765993 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL2800459 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL6025493 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL21645269 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL21645279 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL11801286 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL539662 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL21645321 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL21645312 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1
SCHEMBL8190443 1.00 MAPT (0.58) MAPTLMNAKDM4EDUSP3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113181073-B Composite vitamin emulsion, wrinkle-removing essence cream and preparation method thereof 广州市科能化妆品科研有限公司 2022-12-23 CN claimed
CN-111437214-B Retinol inclusion, anti-aging and wrinkle-removing essence and preparation method thereof 广州市科能化妆品科研有限公司 2022-05-13 CN claimed
CN-113181073-A Composite vitamin emulsion, wrinkle-removing essence cream and preparation method thereof 广州市科能化妆品科研有限公司 2021-07-30 CN claimed
US-20200236933-A1 USE OF A NON-IONIC SURFACTANT WHICH IS A POLYOL DERIVATIVE AS A PLANT GROWTH STIMULATING AGENT OR AS AN ADJUVANT INNOVI (FR) 2020-07-30 US claimed
CN-111437214-A Retinol inclusion, anti-aging and wrinkle-removing essence and preparation method thereof 广州市科能化妆品科研有限公司 2020-07-24 CN claimed
CN-111432640-A Use of nonionic surfactants of polyol derivatives as plant growth stimulators or as adjuvants 宜诺维 2020-07-17 CN claimed
EP-3664610-A2 USE OF A NON-IONIC SURFACTANT WHICH IS A POLYOL DERIVATIVE AS A PLANT GROWTH STIMULATING AGENT OR AS AN ADJUVANT INNOVI (FR) 2020-06-17 EP claimed
US-20180200180-A1 MAGNOLIA BARK EXTRACT AS A HYDROPHOBIC LIGAND FOR PREFERENTIAL REMOVAL OF GRAM NEGATIVE BACTERIA FROM THE ORAL CAVITY WM. WRIGLEY JR. COMPANY 2018-07-19 US claimed
EP-3322487-A1 MAGNOLIA BARK EXTRACT AS A HYDROPHOBIC LIGAND FOR PREFERENTIAL REMOVAL OF GRAM NEGATIVE BACTERIA FROM THE ORAL CAVITY WM. Wrigley Jr. Company (US) 2018-05-23 EP claimed
WO-2017011665-A1 MAGNOLIA BARK EXTRACT AS A HYDROPHOBIC LIGAND FOR PREFERENTIAL REMOVAL OF GRAM NEGATIVE BACTERIA FROM THE ORAL CAVITY WM. WRIGLEY JR. COMPANY (US) 2017-01-19 WO claimed
US-12521350-B2 Liquid crystalline dosage form for administering a statin CUBOPHARM PTY LTD (AU) 2026-01-13 US disclosed
US-12521342-B2 Fast disintegrating tablet CUBOPHARM PTY LTD (AU) 2026-01-13 US disclosed
US-12441934-B2 Viscosifying friction reducers Energy Solutions (US) LLC (US) 2025-10-14 US disclosed
US-12428593-B2 Hydraulic fracturing fluids and methods of use with friction reducer slurry formulation INDEPENDENCE OILFIELD CHEMICALS LLC (US) 2025-09-30 US disclosed
WO-2025102064-A1 FRICTION REDUCER POLYMERS FOR OILFIELD APPLICATIONS Energy Solutions (US) LLC (US) 2025-05-15 WO disclosed
US-5739190-A Process for the preparation of stable water-in-oil emulsions of hydrolyzed polymers of N-vinyl amides and the use thereof BASF AKTIENGESELLSCHAFT (DE) 1998-04-14 US disclosed
WO-1994012651-A1 ENZYMATIC SYNTHESIS OF SUGAR ALCOHOL ESTERS NOVO NORDISK A/S (DK) 1994-06-09 WO disclosed
US-5292800-A Epichlorohydrin, alcohol, polyol, alkoxylation BASF AKTIENGESELLSCHAFT (DE) 1994-03-08 US disclosed
US-5162116-A Intra-ruminal device for delivering drugs COOPERS ANIMAL HEALTH LIMITED (GB) 1992-11-10 US disclosed
EP-0373890-A1 Intra-ruminal device COOPERS ANIMAL HEALTH LIMITED (GB) 1990-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180200180-A1 MAGNOLIA BARK EXTRACT AS A HYDROPHOBIC LIGAND FOR PREFERENTIAL REMOVAL OF GRAM NEGATIVE BACTERIA FROM THE ORAL CAVITY MLEC, CD14, HIRA MAPT 3493/4885LMNA 2010/4885KDM4E 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.